Henning Bliddal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henning Bliddal has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Bente Danneskiold-Samsøe
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, 2000 Frederiksberg, Copenhagen, Denmark
10 shared publications B Jensen
6 shared publicationsA Wiik
2 shared publications- Anette Savnik
Department of Rheumatology, Parker Institute, Frederiksberg Hospital, Copenhagen, Denmark
2 shared publications - Arne Astrup
Obesity and Nutritional Sciences, Novo Nordisk Foundation, Hellerup, Denmark
2 shared publications E. Qvistgaard
2 shared publications
Latest Publications
- 1 December 2013
- Published by Open Access Publishing London in OA Musculoskeletal Medicine
- Vol. 1 (3)
Agreement between measures of walking related knee pain in knee osteoarthritis: A cross-sectional study
- 1 December 2013
- Published by Open Access Publishing London in OA Musculoskeletal Medicine
- Vol. 1 (3)
Agreement between measures of walking related knee pain in knee osteoarthritis: A cross-sectional study
- Open Access
- 5 December 2012
- Published by Springer Nature
A randomized, controlled study of intra-articular injections of etanercept or glucocorticosteroids in patients with rheumatoid arthritis
- 5 December 2012
- Published by Springer Nature
Open AccessA randomized, controlled study of intra-articular injections of etanercept or glucocorticosteroids in patients with rheumatoid arthritis
- 15 June 2007
- Published by Wiley in Obesity Reviews
- Vol. 8 (4) , 377-378
Nutrition and Arthritis. By Margaret Rayman and Alison Callaghan. Blackwell Publishing Ltd., Oxford, 2006, 280 pp., £39.99
- 15 June 2007
- Published by Wiley in Obesity Reviews
- Vol. 8 (4) , 377-378
Nutrition and Arthritis. By Margaret Rayman and Alison Callaghan. Blackwell Publishing Ltd., Oxford, 2006, 280 pp., £39.99
- Top Cited Papers
- 1 April 2007
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (4) , 433-439
Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis
This review aims to assess by meta-analysis of randomised controlled trials (RCTs) changes in pain and function when overweight patients with knee osteoarthritis (OA) achieve a weight loss. Systematic searches were performed and reference lists from the retrieved trials were searched. RCTs were enclosed in the systematic review if they explicitly stated diagnosis of knee OA and reported a weight change as the only difference in intervention from the control group. Outcome Measures for Arthritis Clinical Trials III outcome variables were considered for analysis. Effect size (ES) was calculated using RevMan, and meta-regression analyses were performed using weighted estimates from the random effects analyses. Among 35 potential trials identified, four RCTs including five intervention/control groups met our inclusion criteria and provided data from 454 patients. Pooled ES for pain and physical disability were 0.20 (95% CI 0 to 0.39) and 0.23 (0.04 to 0.42) at a weight reduction of 6.1 kg (4.7 to 7.6 kg). Meta-regression analysis showed that disability could be significantly improved when weight was reduced over 5.1%, or at the rate of >0.24% reduction per week. Clinical efficacy on pain reduction was present, although not predictable after weight loss. Meta-regression analysis indicated that physical disability of patients with knee OA and overweight diminished after a moderate weight reduction regime. The analysis supported that a weight loss of >5% should be achieved within a 20-week period--that is, 0.25% per week.
- 1 April 2007
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (4) , 433-439
Top Cited PapersEffect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis
This review aims to assess by meta-analysis of randomised controlled trials (RCTs) changes in pain and function when overweight patients with knee osteoarthritis (OA) achieve a weight loss. Systematic searches were performed and reference lists from the retrieved trials were searched. RCTs were enclosed in the systematic review if they explicitly stated diagnosis of knee OA and reported a weight change as the only difference in intervention from the control group. Outcome Measures for Arthritis Clinical Trials III outcome variables were considered for analysis. Effect size (ES) was calculated using RevMan, and meta-regression analyses were performed using weighted estimates from the random effects analyses. Among 35 potential trials identified, four RCTs including five intervention/control groups met our inclusion criteria and provided data from 454 patients. Pooled ES for pain and physical disability were 0.20 (95% CI 0 to 0.39) and 0.23 (0.04 to 0.42) at a weight reduction of 6.1 kg (4.7 to 7.6 kg). Meta-regression analysis showed that disability could be significantly improved when weight was reduced over 5.1%, or at the rate of >0.24% reduction per week. Clinical efficacy on pain reduction was present, although not predictable after weight loss. Meta-regression analysis indicated that physical disability of patients with knee OA and overweight diminished after a moderate weight reduction regime. The analysis supported that a weight loss of >5% should be achieved within a 20-week period--that is, 0.25% per week.
- 9 January 2007
- Vol. 24 (6) , 664-9
Imaging of intratendinous distribution of glucocorticosteroid in the treatment of Achilles tendinopathy. Pilot study of low-field magnetic resonance imaging correlated with ultrasound.
Recently, a positive treatment effect of intratendinous injections of steroid in Achilles tendonitis (AT) has been described. Our aim was to test the localization and distribution of the injected steroid in both healthy (animal) tendons and in diseased human Achilles tendons. Four pig tendons were injected in vivo and harvested. The harvested tendons were placed in 0.2 Tesla MRI scanner, in order to select the optimal MRI sequences for tracking and localizing the bolus injection. Three patients with AT were treated with intratendinous steroid injection. Injections were placed in the pathologic areas of the tendon guided by ultrasound (US). MRI and US were performed at baseline and again immediately and 60 minutes after injection. A final follow-up MRI was performed 1 month after the injection. In the animal model, significant recoil of the injected substance was seen in all cases. In all three patients the injection was readily distributed within the tendon and no recoil through the injection channel was found. One-month follow-up showed a total regression of hyperaemia on US as well as regression of intratendinous oedema on MRI in all 3 patients. It is possible to demonstrate the distribution pattern of injected steroid in diseased Achilles tendons by MR-imaging. In contrast to the recoil experienced in the healthy tendon of the animal, the lack of recoil of the injected volume through the injection channel in the sick human tendon may be caused by a derangement of the fibre structure, which allows the extra volume to be distributed within the lesion. This indicates that the effect on AT of intra-tendinous injections of steroid is due to a local intra-tendinous action of the drug.
- 9 January 2007
- Vol. 24 (6) , 664-9
Imaging of intratendinous distribution of glucocorticosteroid in the treatment of Achilles tendinopathy. Pilot study of low-field magnetic resonance imaging correlated with ultrasound.
Recently, a positive treatment effect of intratendinous injections of steroid in Achilles tendonitis (AT) has been described. Our aim was to test the localization and distribution of the injected steroid in both healthy (animal) tendons and in diseased human Achilles tendons. Four pig tendons were injected in vivo and harvested. The harvested tendons were placed in 0.2 Tesla MRI scanner, in order to select the optimal MRI sequences for tracking and localizing the bolus injection. Three patients with AT were treated with intratendinous steroid injection. Injections were placed in the pathologic areas of the tendon guided by ultrasound (US). MRI and US were performed at baseline and again immediately and 60 minutes after injection. A final follow-up MRI was performed 1 month after the injection. In the animal model, significant recoil of the injected substance was seen in all cases. In all three patients the injection was readily distributed within the tendon and no recoil through the injection channel was found. One-month follow-up showed a total regression of hyperaemia on US as well as regression of intratendinous oedema on MRI in all 3 patients. It is possible to demonstrate the distribution pattern of injected steroid in diseased Achilles tendons by MR-imaging. In contrast to the recoil experienced in the healthy tendon of the animal, the lack of recoil of the injected volume through the injection channel in the sick human tendon may be caused by a derangement of the fibre structure, which allows the extra volume to be distributed within the lesion. This indicates that the effect on AT of intra-tendinous injections of steroid is due to a local intra-tendinous action of the drug.
- 1 January 2007
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 36 (6) , 411-417
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
Objective: To compare the efficacy of adalimumab, etanercept, and infliximab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX) by calculating the number needed to treat (NNT) using three different methods. Methods: A systematic literature search of the Cochrane Library, MEDLINE, and EMBASE was conducted from inception to 30 June 2006. Two pairs of investigators, a Danish and a Swedish pair, independently conducted a structured literature review. The reviewers selected any published randomized, double-blind, MTX controlled study of adalimumab, etanercept, and infliximab, presenting the American College of Rheumatology 50% response (ACR50) after 12 months in RA patients with a mean disease duration of at least 5 years. The two review groups independently extracted the estimates necessary to calculate the NNT. Results: The reviewers consistently selected the same three randomized, controlled trials (RCTs), one for each of the drugs, and extracted equal data for the number of patients completing the 12-month intervention, and the corresponding number of ACR50 responding patients after therapy. Some baseline differences were noted: patients in the etanercept trial had a shorter disease duration and did not receive MTX prior to inclusion; patients in the adalimumab study had lower Health Assessment Questionnaire (HAQ) scores. The calculated NNTs varied slightly depending on the method used. The fully adjusted NNTs (95% confidence intervals) for adalimumab, etanercept, infliximab standard dosage and infliximab double dosage were 4 (3-6), 4 (3-6), 8 (4-66), and 4 (3-11) patients, respectively. Conclusion: This study indicates equal efficacy of the three anti-tumour necrosis factor (TNF) therapies
- 1 January 2007
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 36 (6) , 411-417
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
Objective: To compare the efficacy of adalimumab, etanercept, and infliximab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX) by calculating the number needed to treat (NNT) using three different methods. Methods: A systematic literature search of the Cochrane Library, MEDLINE, and EMBASE was conducted from inception to 30 June 2006. Two pairs of investigators, a Danish and a Swedish pair, independently conducted a structured literature review. The reviewers selected any published randomized, double-blind, MTX controlled study of adalimumab, etanercept, and infliximab, presenting the American College of Rheumatology 50% response (ACR50) after 12 months in RA patients with a mean disease duration of at least 5 years. The two review groups independently extracted the estimates necessary to calculate the NNT. Results: The reviewers consistently selected the same three randomized, controlled trials (RCTs), one for each of the drugs, and extracted equal data for the number of patients completing the 12-month intervention, and the corresponding number of ACR50 responding patients after therapy. Some baseline differences were noted: patients in the etanercept trial had a shorter disease duration and did not receive MTX prior to inclusion; patients in the adalimumab study had lower Health Assessment Questionnaire (HAQ) scores. The calculated NNTs varied slightly depending on the method used. The fully adjusted NNTs (95% confidence intervals) for adalimumab, etanercept, infliximab standard dosage and infliximab double dosage were 4 (3-6), 4 (3-6), 8 (4-66), and 4 (3-11) patients, respectively. Conclusion: This study indicates equal efficacy of the three anti-tumour necrosis factor (TNF) therapies
- 11 December 2006
- Vol. 168 (50) , 4405-9
[Glucosamine effectiveness in the treatment of knee osteoarthritis. Presentation of a Cochrane analysis with the perspective on the GAIT trial].
- 11 December 2006
- Vol. 168 (50) , 4405-9
[Glucosamine effectiveness in the treatment of knee osteoarthritis. Presentation of a Cochrane analysis with the perspective on the GAIT trial].
- 1 December 2006
- Published by Elsevier in Joint Bone Spine
- Vol. 73 (6) , 714-717
Safety of intra-articular injection of etanercept in small-joint arthritis: an uncontrolled, pilot-study with independent imaging assessment
- 1 December 2006
- Published by Elsevier in Joint Bone Spine
- Vol. 73 (6) , 714-717
Safety of intra-articular injection of etanercept in small-joint arthritis: an uncontrolled, pilot-study with independent imaging assessment
- Open Access
- 6 May 2006
- Published by Springer Nature in European Spine Journal
- Vol. 16 (2) , 277-282
Intra-observer and inter-observer agreement of the manual examination of the lumbar spine in chronic low-back pain
Examination is a cornerstone in the manual procedures leading to mobilisation/manipulation of the low back. The observer variation of the more specific segmental tests remains to be investigated. Two skilled specialists in manual medicine examined the segmental changes in the lumbar spine. The patients were unknown to the examiners and no information of the case history was given. All test results were recorded by an observer present in the room who ensured that no conversation was allowed during the examination. The primary outcome measures were the kappa values for each test. The matching was defined as acceptable (acc) within two neighbouring levels and perfect (per) on the same level. Intra-observer variation (tested in 33 patients and 10 subjects without low-back pain): The agreement between first and second segmental diagnosis examination was 70% (per) and 82% (per + acc). Kappa values were: segmental diagnosis 0.60 (per) and 0.70 (per + acc), multifidus test 0.51 (per) and 0.60 (per + acc), sideflexion 0.57 (per) and 0.69 (per + acc), and ventral flexion 0.31 (per) and 0.45 (per + acc). Inter-observer variation (tested in 60 patients): The agreement for segmental diagnosis between the examiner A and B was 42% (per) and 75% (per + acc). Kappa values were: segmental diagnosis 0.21 (per) and 0.57 (acc), multifidus test 0.12 (per) and 0.48 (acc), sideflexion 0.22 (per) and 0.45 (acc), and ventralflexion 0.22 (per) and 0.44 (acc). By manual tests, skilled examiners seem to be able to diagnose segmental dysfunctions in the low back. The clinical implication of these dysfunctions remains to be clarified.
- 6 May 2006
- Published by Springer Nature in European Spine Journal
- Vol. 16 (2) , 277-282
Open AccessIntra-observer and inter-observer agreement of the manual examination of the lumbar spine in chronic low-back pain
Examination is a cornerstone in the manual procedures leading to mobilisation/manipulation of the low back. The observer variation of the more specific segmental tests remains to be investigated. Two skilled specialists in manual medicine examined the segmental changes in the lumbar spine. The patients were unknown to the examiners and no information of the case history was given. All test results were recorded by an observer present in the room who ensured that no conversation was allowed during the examination. The primary outcome measures were the kappa values for each test. The matching was defined as acceptable (acc) within two neighbouring levels and perfect (per) on the same level. Intra-observer variation (tested in 33 patients and 10 subjects without low-back pain): The agreement between first and second segmental diagnosis examination was 70% (per) and 82% (per + acc). Kappa values were: segmental diagnosis 0.60 (per) and 0.70 (per + acc), multifidus test 0.51 (per) and 0.60 (per + acc), sideflexion 0.57 (per) and 0.69 (per + acc), and ventral flexion 0.31 (per) and 0.45 (per + acc). Inter-observer variation (tested in 60 patients): The agreement for segmental diagnosis between the examiner A and B was 42% (per) and 75% (per + acc). Kappa values were: segmental diagnosis 0.21 (per) and 0.57 (acc), multifidus test 0.12 (per) and 0.48 (acc), sideflexion 0.22 (per) and 0.45 (acc), and ventralflexion 0.22 (per) and 0.44 (acc). By manual tests, skilled examiners seem to be able to diagnose segmental dysfunctions in the low back. The clinical implication of these dysfunctions remains to be clarified.